Phase I/II study of LAG525 +/- spartalizumab (PDR001) in patients (pts) with advanced malignancies.

Hong, DS; Schoffski, P; Calvo, A; Sarantopoulos, J; De Olza, MO; Carvajal, RD

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (15):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索